Citeline, a Norstella company

Novo Nordisk said it will take legal action against mass compounding of the new oral semaglutide formulation by Hims & Hers.

Given its already large cancer drug pipeline, EVP of oncology R&D Susan Galbraith spoke with Scrip about how AstraZeneca is making precise choices about deals and development programs.

The headlines showed a robust tally of new drug approvals from the US FDA in 2025, but cracks are beginning to show that could turn into fissures in the year ahead.

Recent moves in the industry include internal moves at Immunocore, Ipsen and Merck KGaA, plus BioNTech gets a new chief people officer.

Everest Medicine obtains selected commercialization rights to first-in-class, Phase III stage bispecific peptide MT1013 from Shanxi Micot Technology at home. A trial for secondary hyperparathyroidism is due to be completed by year-end in China.

Among the Chinese AI firms raising new funding, Deep Intelligent Pharma has bagged a total of $110m in two rounds of funding since last December, while Levinthal, OxTium and Aureka have also closed new investment rounds.

Sunshine Pharma plans to invest at least $14m to set up a joint venture with fellow Chinese firm XtalPi, with goals including the discovery and development of novel molecules for autoimmune disorders.

Following the recent acceptance of a China NDA for first-in-class drug denifanstat for acne in China, Ascletis has announced positive topline results from an open-label Phase III trial focusing on the product’s long-term safety.